Michaela Liedtke
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments 51
- Acute Myeloid Leukemia Research 23
- Chronic Myeloid Leukemia Treatments 17
- Oncology top 1%
- CAR-T cell therapy research 32
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 29
- Nephrology top 2%
-
- Acute Lymphoblastic Leukemia research 40
-
- Amyloidosis: Diagnosis, Treatment, Outcomes 57
-
- Neuroendocrine Tumor Research Advances 17
- Co-authors
- Ronald WittelesAnjali S. AdvaniDaniel J. DeAngeloWendy StockErik VandendriesHagop M. KantarjianMatthias StelljesNicola Gökbuget
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Michaela Liedtke
159 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 110
- Hematology 1.7k
- Oncology 2.1k
- Genetics 624
- Nephrology 294
- Public Health, Environmental and Occupational Health 1.2k
Countries citing papers authored by Michaela Liedtke
This map shows the geographic impact of Michaela Liedtke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaela Liedtke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaela Liedtke more than expected).
Fields of papers citing papers by Michaela Liedtke
This network shows the impact of papers produced by Michaela Liedtke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaela Liedtke. The network helps show where Michaela Liedtke may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michaela Liedtke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2022 | 6 | |
| 3 | 2021 | 17 | |
| 4 | 2021 | 70 | |
| 5 | 2019 | 37 | |
| 6 | 2019 | 34 | |
| 7 | 2018 | 24 | |
| 8 | 2018 | 27 | |
| 9 | 2017 | 15 | |
| 10 | 2017 | 179 | |
| 11 | 2017 | 5 | |
| 12 | 2017 | 58 | |
| 13 | 2017 | 2 | |
| 14 | 2016 | 147 | |
| 15 | 2016 | 48 | |
| 16 | 2015 | 32 | |
| 17 | 2015 | 89 | |
| 18 | 2013 | 144 | |
| 19 | 2006 | 71 | |
| 20 | 1992 | 118 |
About Michaela Liedtke
Michaela Liedtke is a scholar working on Hematology, Genetics and Oncology, having authored 167 papers that have together received 5.0k indexed citations. Recurring topics across this work include Amyloidosis: Diagnosis, Treatment, Outcomes (57 papers), Multiple Myeloma Research and Treatments (51 papers), Acute Lymphoblastic Leukemia research (40 papers), CAR-T cell therapy research (32 papers), Chronic Lymphocytic Leukemia Research (29 papers), Acute Myeloid Leukemia Research (23 papers), Neuroendocrine Tumor Research Advances (17 papers) and Chronic Myeloid Leukemia Treatments (17 papers). The work is most often cited by research in Hematology (1.7k citations), Oncology (2.1k citations) and Genetics (624 citations). Michaela Liedtke has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Ronald Witteles, Anjali S. Advani, Daniel J. DeAngelo, Wendy Stock, Erik Vandendries, Hagop M. Kantarjian, Matthias Stelljes, Nicola Gökbuget, Susan O’Brien and Barbara Sleight. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Haematologica and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.